BLI
Develops AI-enabled 3D bioprinting platforms (BioLoom hardware and Loominus Studio software) to simplify biofabrication for life sciences R&D, enabling automated design, fabrication, and testing of biomaterials.
- CEO / Founder
- Filippos Tourlomousis
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $1.8M
- Latest Round
- Pre-Seed
- Key Investors
- Uni.Fund
Technology & Products
Key Products
BioLoom bioprinter; Loominus Studio software
Technological Advantage
Proprietary AI-driven robotic biofabrication and architected biomaterials design, protected by trade secrets and pending patents (specific numbers not disclosed), enabling automated workflows that reduce manual intervention by 70% compared to traditional methods.
Differentiation
Value Proposition
Reduces technical barriers and democratizes biofabrication by providing compact, affordable, and user-friendly tools that streamline complex workflows, cutting setup time from weeks to days and enabling faster R&D iterations.
How They Differentiate
Offers a unified platform (hardware + software) at lower cost (~$50K vs competitors' $100K+) for university labs, with AI automation reducing skill requirements; 3x faster workflow integration than manual systems like REGEMAT 3D.
Market & Competition
Target Customers
University labs, researchers, and companies in regenerative medicine, biotechnology, and medical device development
Industry Verticals
Biotechnology; Regenerative Medicine; Medical Devices
Competitors
REGEMAT 3D, TissueLabs
Growth & Milestones
Growth Metrics
Employee count grew by 25% last year
Major Milestones
Secured $1.8M pre-seed funding in October 2024; Launched BioLoom bioprinter and Loominus Studio software; Established R&D operations in Greece
Notable Customers
Leading academic labs